Literature DB >> 2702801

Influence of debrisoquin phenotype on the inducibility of propranolol metabolism.

O Shaheen1, J Biollaz, R P Koshakji, G R Wilkinson, A J Wood.   

Abstract

The effects of rifampin (600 mg) once daily for 22 days on the total and fractional metabolic clearances of propranolol were determined in a group of six genetically extensive (EM) and six poor metabolizers (PM) of debrisoquin. The impaired ability of PMs to metabolize propranolol to the ring-oxidized metabolite 4-hydroxypropranolol was confirmed. The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs. The extent of induction of glucuronidation was similar in the two groups. 4-Hydroxylation was induced in both phenotypes but the increase was fifteenfold greater in EMs than in PMs. This would imply that the cytochrome P-450 determined by the debrisoquin allele or some coinherited 4-hydroxylase(s) was induced to a greater extent in EMs than PMs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702801     DOI: 10.1038/clpt.1989.52

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants.

Authors:  Narendranath Epperla; Murray H Brilliant; Humberto Vidaillet
Journal:  BMJ Case Rep       Date:  2014-02-11

2.  Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.

Authors:  H H Zhou; L B Anthony; A J Wood; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

3.  Propranolol oxidation by human liver microsomes--the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity.

Authors:  S V Otton; E M Gillam; M S Lennard; G T Tucker; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 4.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.

Authors:  A Ebihara; A Fujimura
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.